MCID: GLL018
MIFTS: 55

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 54 38 56 44 15
Gallbladder Carcinoma 12 56 15 17 74
Gallbladder Neoplasm 12 17 74
Malignant Neoplasm of Gallbladder 12 74
Carcinoma of Gallbladder 12 6
Malignant Neoplasm of Gallbladder Localized 74
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 45
Gallbladder Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3121 DOID:4948
KEGG 38 H00047
ICD9CM 36 156.0
MeSH 45 D005706
SNOMED-CT 69 93810008
ICD10 34 C23

Summaries for Gallbladder Cancer

MedlinePlus : 44 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are MAPK Pathway and DNA Damage Response (only ATM dependent). The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and lung.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 77 Gallbladder cancer is a relatively uncommon cancer, with an incidence of fewer than 2 cases per 100,000... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.4 AFAP1-AS1 ERBB2 H19 MALAT1 PIK3CA TP53
2 adenocarcinoma 30.4 ERBB2 H19 MALAT1 PIK3CA TP53
3 kidney cancer 30.0 H19 HOTAIR MALAT1 MEG3 TP53
4 retinoblastoma 29.9 CCAT1 HOTAIR MALAT1 MEG3 TP53
5 bladder cancer 29.9 CDKN2B-AS1 ERBB2 H19 HOTAIR MALAT1 MEG3
6 squamous cell carcinoma 29.7 CDKN2B-AS1 ERBB2 H19 HOTAIR MALAT1 PIK3CA
7 melanoma 29.3 CDKN2B-AS1 H19 HOTAIR HOXA-AS2 LINC-ROR MALAT1
8 renal cell carcinoma, nonpapillary 29.2 CCAT1 CRNDE CYTOR H19 HOTAIR LINC-ROR
9 ovarian cancer 28.6 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE ERBB2 H19
10 pancreatic cancer 28.5 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE CYTOR ERBB2
11 lung cancer 28.5 AFAP1-AS1 CCAT1 CDKN2B-AS1 ERBB2 FENDRR H19
12 hepatocellular carcinoma 28.4 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE CYTOR H19
13 breast cancer 28.4 CCAT1 CDKN2B-AS1 CRNDE CYTOR ERBB2 H19
14 adenosquamous gallbladder carcinoma 12.5
15 gallbladder small cell carcinoma 11.4
16 bile duct cancer 11.4
17 biliary tract cancer 11.4
18 gallbladder squamous cell carcinoma 11.1
19 gallbladder papillary carcinoma 11.1
20 gastric papillary adenocarcinoma 10.5 ERBB2 TP53
21 cholecystitis 10.5
22 adult hepatocellular carcinoma 10.5 PIK3CA TP53
23 uterine corpus serous adenocarcinoma 10.5 ERBB2 PIK3CA TP53
24 breast squamous cell carcinoma 10.5 ERBB2 PIK3CA TP53
25 uterine body mixed cancer 10.5 ERBB2 PIK3CA TP53
26 rare adenocarcinoma of the breast 10.5 PIK3CA TP53
27 uterine corpus cancer 10.5 ERBB2 PIK3CA TP53
28 malignant spiradenoma 10.5 PIK3CA TP53
29 ovary adenocarcinoma 10.5 ERBB2 PIK3CA TP53
30 esophagus adenocarcinoma 10.5 AFAP1-AS1 ERBB2 TP53
31 ovarian cancer 1 10.5 ERBB2 PIK3CA TP53
32 malignant ovarian surface epithelial-stromal neoplasm 10.5 ERBB2 PIK3CA TP53
33 vulva squamous cell carcinoma 10.5 MALAT1 MEG3 TP53
34 ovary epithelial cancer 10.5 ERBB2 PIK3CA TP53
35 functionless pituitary adenoma 10.5 HOTAIR MEG3
36 serous cystadenocarcinoma 10.5 ERBB2 PIK3CA TP53
37 pleomorphic adenoma carcinoma 10.5 ERBB2 TP53
38 cystadenocarcinoma 10.5 ERBB2 PIK3CA TP53
39 estrogen-receptor positive breast cancer 10.5 ERBB2 PIK3CA TP53
40 endometrial adenocarcinoma 10.4 ERBB2 MALAT1 TP53
41 uterine anomalies 10.4 ERBB2 PIK3CA TP53
42 carcinosarcoma 10.4 ERBB2 PIK3CA TP53
43 marek disease 10.4 H19 TP53
44 ovarian serous cystadenocarcinoma 10.4 ERBB2 PIK3CA TP53
45 bladder disease 10.4 ERBB2 TP53 UCA1
46 triple-receptor negative breast cancer 10.4 HOTAIR LINC-ROR MALAT1
47 respiratory system cancer 10.4 ERBB2 MALAT1 PIK3CA TP53
48 non-proliferative fibrocystic change of the breast 10.4 ERBB2 TP53
49 uterine carcinosarcoma 10.4 ERBB2 PIK3CA TP53
50 breast adenocarcinoma 10.4 ERBB2 H19 PIK3CA TP53

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Ulipristal acetate Phase 4 126784-99-4
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
8
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
9
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
10
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 143 6006
11
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605
12
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
18
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
20
Citalopram Approved Phase 3 59729-33-8 2771
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
22 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
28 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Analgesics Phase 3,Phase 1
33 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
34 Hormone Antagonists Phase 3
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
36 Hormones Phase 3,Phase 2,Phase 1
37 Ether Phase 3,Phase 2
38 Dihematoporphyrin Ether Phase 3,Phase 2
39 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Photosensitizing Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Narcotics Phase 3
42 Adjuvants, Anesthesia Phase 3
43 Anesthetics, Intravenous Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics Phase 3
46 Analgesics, Opioid Phase 3
47 Central Nervous System Depressants Phase 3
48
protease inhibitors Phase 3
49 Tranquilizing Agents Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
4 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
5 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
6 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
7 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
8 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
9 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
10 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
11 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
14 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
15 Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
16 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
17 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
18 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
19 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
20 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
21 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
22 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
23 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
24 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
25 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
26 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
27 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
28 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
29 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
30 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
31 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
32 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
33 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
34 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
35 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
36 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
37 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
38 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
39 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
40 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
41 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
42 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
43 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
44 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
45 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
46 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
47 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
48 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
49 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
50 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

MalaCards organs/tissues related to Gallbladder Cancer:

42
Liver, Lymph Node, Lung, Breast, Eye, Skin, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

20
The Gallbladder

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 2219)
# Title Authors Year
1
Extended resection for xanthogranulomatous cholecystitis mimicking gallbladder carcinoma: Cases and review of diagnostic approach. ( 30804596 )
2019
2
Totally Laparoscopic Radical Cholecystectomy for Gallbladder Cancer: A Single Center Experience. ( 31074684 )
2019
3
Liensinine induces gallbladder cancer apoptosis and G2/M arrest by inhibiting ZFX-induced PI3K/AKT pathway. ( 31074773 )
2019
4
Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer. ( 29943183 )
2019
5
Incidental Gallbladder Cancer: How Residual Disease Affects Outcome in Two Referral HPB Centers from South America. ( 30105638 )
2019
6
E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. ( 30254209 )
2019
7
Resection of Hepatic Lesions Perfused by the Cholecystic Vein Using Indocyanine Green Navigation in Patients with cT2 Gallbladder Cancer. ( 30267293 )
2019
8
CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer. ( 30276551 )
2019
9
The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review. ( 30287098 )
2019
10
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. ( 30304546 )
2019
11
Surgery in node-positive gallbladder cancer: The implication of an involved superior retro-pancreatic lymph node. ( 30348459 )
2019
12
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. ( 30427539 )
2019
13
Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient. ( 30461064 )
2019
14
National Failure of Surgical Staging for T1b Gallbladder Cancer. ( 30499077 )
2019
15
Comparison of Laparoscopic and Open Approach in Treating Gallbladder Cancer. ( 30527484 )
2019
16
Systematic review of management of incidental gallbladder cancer after cholecystectomy. ( 30582640 )
2019
17
The diagnostic accuracy of CT and MRI for the detection of lymph node metastases in gallbladder cancer: A systematic review and meta-analysis. ( 30599854 )
2019
18
Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer. ( 30610554 )
2019
19
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin. ( 30611225 )
2019
20
Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study. ( 30616645 )
2019
21
PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). ( 30666556 )
2019
22
Effects of claudin-1 downregulation on the physiological processes of gallbladder cancer SGC996 cells. ( 30675228 )
2019
23
Tumor Protein p53 and K-ras Gene Mutations in Peruvian Patients with Gallbladder Cancer ( 30678452 )
2019
24
Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator. ( 30704808 )
2019
25
Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review. ( 30707412 )
2019
26
Incidental versus non-incidental gallbladder cancer: index cholecystectomy before oncologic re-resection negatively impacts survival in T2b tumors. ( 30711243 )
2019
27
Is laparoscopy contraindicated for advanced gallbladder cancer? ( 30737024 )
2019
28
Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer. ( 30740890 )
2019
29
Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer. ( 30755649 )
2019
30
Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. ( 30762874 )
2019
31
Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway. ( 30775814 )
2019
32
Robotic surgery for gallbladder cancer: Operative technique and early outcomes. ( 30802316 )
2019
33
SLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer. ( 30814911 )
2019
34
Impact of Body Mass Index of Japanese Gallbladder Cancer Patients on their Postoperative Outcomes. ( 30820054 )
2019
35
aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1. ( 30822690 )
2019
36
Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. ( 30825877 )
2019
37
A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with advanced gallbladder cancer receiving chemotherapy. ( 30842131 )
2019
38
Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies. ( 30846038 )
2019
39
Minimally Invasive Surgery for Gallbladder Cancer. ( 30851826 )
2019
40
Laparoscopic radical cholecystectomy with common bile duct resection for T2 gallbladder cancer. ( 30863811 )
2019
41
The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients. ( 30864246 )
2019
42
Prognostic Impact of Lymph Node Excision in T1 and T2 Gallbladder Cancer: a Population-Based and Propensity Score-Matched SEER Analysis. ( 30887297 )
2019
43
cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro. ( 30902881 )
2019
44
SP/NK-1R promotes gallbladder cancer cell proliferation and migration. ( 30903649 )
2019
45
Glucose to Lymphocyte Ratio as a Prognostic Marker in Patients With Resected pT2 Gallbladder Cancer. ( 30909062 )
2019
46
A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer. ( 30922845 )
2019
47
Calcified gallbladder cancer: is it preventable? ( 30949330 )
2019
48
Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. ( 30953511 )
2019
49
[Corrigendum] Metformin suppresses hypoxia‑induced migration via the HIF‑1α/VEGF pathway in gallbladder cancer in vitro and in vivo. ( 31002375 )
2019
50
Staging gallbladder cancer with lymphadenectomy: the practical application of new AHPBA and AJCC guidelines. ( 31010632 )
2019

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6 (show all 45)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
8 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
10 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
11 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
12 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
15 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
16 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
17 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
20 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
21 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh38 Chromosome 17, 39725079: 39725079
22 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
23 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
24 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
25 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
26 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
27 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
28 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh37 Chromosome 17, 7578393: 7578393
29 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh38 Chromosome 17, 7675075: 7675075
30 TP53 NM_000546.5(TP53): c.536A> T (p.His179Leu) single nucleotide variant Uncertain significance rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
31 TP53 NM_000546.5(TP53): c.536A> T (p.His179Leu) single nucleotide variant Uncertain significance rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
32 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
33 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
34 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
35 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
36 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
37 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
38 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
39 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
40 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
41 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
42 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
43 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242
44 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
45 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.64 ERBB2 PIK3CA TP53
2 11.56 ERBB2 PIK3CA TP53
3 11.3 ERBB2 PIK3CA TP53
4 11.15 ERBB2 PIK3CA TP53
5 10.94 ERBB2 PIK3CA TP53
6 10.1 HOTAIR LINC-ROR MEG3 TP53 UCA1

GO Terms for Gallbladder Cancer

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....